We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Shark-Derived Antibodies in Alzheimer’s Disease Therapy

Shark-Derived Antibodies in Alzheimer’s Disease Therapy content piece image
Biolegend
Read time: Less than a minute

The greatest challenge in developing therapies for Alzheimer’s disease (AD) is to find a way to get therapeutic drugs across the blood-brain barrier (BBB). The BBB is a protective barrier that is made up of cells around the cerebral blood vessels and prevents foreign substances that circulate in the blood from entering the brain.

The protective nature of this barrier also restricts large molecules such as therapeutic antibodies to pass through the BBB and reach their target within the brain. Scientists have created a new proprietary technology to circumvent the BBB impermeability using a shark-derived antibody. This method works in a similar manner to a Trojan horse, where the shark antibody can be used as a transporter for therapeutic antibodies and allow their delivery across the BBB into the brain. This strategy has a great potential to reverse the damage caused by toxic proteins involved in the pathogenesis of AD.

Learn more about amyloid beta, a toxic protein associated with AD



Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.